Can medical cannabis reduce autism-like behaviors in a genetic mouse model?
Long-term oral treatment with CBD-enriched cannabis oil reduced anxiety and decreased repetitive grooming by over 70% in a Shank3 autism mouse model, with evidence suggesting THC, not CBD alone, drove the behavioral improvements.
Quick Facts
What This Study Found
CBD-enriched medical cannabis oil reduced repetitive grooming by over 70% and alleviated anxiety in Shank3 mutant mice. The effects involved CB1 receptor signaling and reduced cerebrospinal fluid glutamate levels. RNA sequencing revealed changes in neurotransmission-related gene expression. Importantly, the results questioned the relevance of CBD enrichment, suggesting THC was the critical component for treating core ASD symptoms.
Key Numbers
Over 70% reduction in repetitive grooming; reduced CSF glutamate; CB1 receptor involvement confirmed; RNA sequencing showed neurotransmission gene changes; THC appeared more important than CBD for behavioral effects
How They Did This
Controlled animal study using Shank3 mutant mice (a human mutation-based autism model). Long-term oral treatment with CBD-enriched medical cannabis oil (Avidekel). Behavioral testing for anxiety and repetitive behaviors. Biochemical analysis of CB1R signaling, CSF glutamate, and RNA sequencing of cerebellar tissue.
Why This Research Matters
No approved treatments exist for the core symptoms of autism. Finding that medical cannabis reduces both repetitive behavior and anxiety in a genetically relevant autism model is significant, especially the insight that THC rather than CBD may be the more important therapeutic component.
The Bigger Picture
The clinical interest in CBD for autism has far outpaced the evidence, partly because CBD is perceived as safer than THC. This study's finding that THC may be more therapeutically relevant challenges the CBD-first approach and suggests the non-intoxicating component alone may not be sufficient.
What This Study Doesn't Tell Us
Animal model of one specific autism-causing mutation (Shank3); autism has hundreds of genetic causes. Mouse behavior does not fully model human ASD. Single cannabis formulation tested.
Questions This Raises
- ?Would THC-dominant formulations be more effective than CBD-dominant ones for autism?
- ?Can the glutamate reduction explain the behavioral improvements?
- ?How do these findings translate to the diverse genetic landscape of human ASD?
Trust & Context
- Key Stat:
- 70% reduction in repetitive grooming
- Evidence Grade:
- Well-designed animal study with genetic autism model, multiple outcome measures, and RNA sequencing, but preclinical only.
- Study Age:
- Published in 2021; clinical trials of cannabis for autism are ongoing.
- Original Title:
- Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.
- Published In:
- Translational psychiatry, 11(1), 524 (2021)
- Authors:
- Poleg, Shani(2), Kourieh, Emad, Ruban, Angela, Shapira, Guy, Shomron, Noam, Barak, Boaz, Offen, Daniel
- Database ID:
- RTHC-03434
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can cannabis help with autism?
In this genetic mouse model, medical cannabis oil reduced repetitive behaviors by over 70% and alleviated anxiety. However, these are animal findings and clinical trials in humans are still ongoing.
Is CBD or THC better for autism?
Despite using a CBD-enriched formulation, the researchers found evidence that THC was the more important component for reducing repetitive and social behavior deficits. This challenges the common preference for CBD-only products in autism.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03434APA
Poleg, Shani; Kourieh, Emad; Ruban, Angela; Shapira, Guy; Shomron, Noam; Barak, Boaz; Offen, Daniel. (2021). Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.. Translational psychiatry, 11(1), 524. https://doi.org/10.1038/s41398-021-01612-3
MLA
Poleg, Shani, et al. "Behavioral aspects and neurobiological properties underlying medical cannabis treatment in Shank3 mouse model of autism spectrum disorder.." Translational psychiatry, 2021. https://doi.org/10.1038/s41398-021-01612-3
RethinkTHC
RethinkTHC Research Database. "Behavioral aspects and neurobiological properties underlying..." RTHC-03434. Retrieved from https://rethinkthc.com/research/poleg-2021-behavioral-aspects-and-neurobiological
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.